Recall report: Nostrum recalls another lot of metformin as carcinogen concerns continue
For the second time in January and the third time in the last two months, a Kansas City, MO laboratory has pulled a lot of generic metformin from the shelves after it was found to contain higher-than-allowed levels of a probable human carcinogen.
The FDA on Tuesday announced that Nostrum Laboratories was voluntarily recalling a lot of metformin HCl extended release tablets, USP 750 mg, a type 2 diabetes drug (the generic equivalent to Glucophage tablets) after testing discovered elevated levels of nitrosamine, the probable carcinogen.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
